Samsung Biologics has launched a new high-concentration formulation platform, S-HiCon, designed to support the development of high-dose biopharmaceuticals. The platform is aimed at improving formulation stability, reducing viscosity, and ensuring the efficacy of drugs with high concentration requirements. The platform
Catalent, Inc. has signed a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, New Jersey, to Ardena, a contract development and manufacturing organisation (CDMO). Ardena operates facilities in Belgium, Spain, the Netherlands, and Sweden.
Nipro PharmaPackaging has announced the launch of its new D2F (Direct-to-Fill) glass vials, featuring Stevanato Group’s EZ-fill® technology. These vials are aimed at meeting the growing demands of the pharmaceutical sector for high-quality, ready-to-use packaging solutions. The D2F vials are
Novotech, a global full-service clinical contract research organisation (CRO), has been awarded the 2024 Global Company of the Year Award by Frost & Sullivan. This award recognises the company’s ability to drive innovation in clinical development, offer advanced technological solutions,
GenScript Biotech Corporation has been upgraded to an A rating in its Environmental, Social, and Governance (ESG) score by MSCI, a globally respected rating agency. MSCI evaluates thousands of companies globally, assessing their ESG performance and risk management. The agency’s
Evonik has announced plans to reorganise its Health Care business to focus on core growth areas such as complex active pharmaceutical ingredients (APIs), drug delivery systems, and biosolutions like lipids for mRNA and gene therapies. As part of this transformation,
Radiopharmaceuticals, a class of drugs that contain radioactive isotopes, are revolutionising the landscape of nuclear medicine, offering unprecedented opportunities for both diagnostic imaging and therapeutic applications. These sophisticated compounds are at the forefront of medical innovation, providing clinicians with powerful
Alfasigma has rebranded its Contract Development and Manufacturing Organisation (CDMO) Business Unit as Morpho, a new identity designed to reflect the unit’s growth and leadership in the pharmaceutical sector. Established in 2017, Alfasigma’s CDMO Business Unit has shown consistent growth,
Lipocine Inc., a biopharmaceutical company specialising in oral drug delivery technologies, has entered into an exclusive supply and distribution agreement with Pharmalink to commercialise TLANDO, its oral testosterone replacement therapy, across the Gulf Cooperation Council (GCC) region. The agreement covers
Arbele, a biopharmaceutical company focusing on cadherin-17 (CDH17), has announced strategic partnerships in precision oncology aimed at advancing immunotherapeutics. These collaborations, involving BioAI Health and Chime Biologics, are expected to enhance the development of bispecific T-cell engagers (TCEs) and antibody-drug
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
